Bottom line
- Long-term investing: WAIT. Do not buy at about $152. NVIDIA is a superb business, with ROIC of 113.9% against a WACC of 13.03%. But the fundamental analyst's expected value is about $107, and the suggested buy zone is $100–120. At today's price there is no margin of safety.
- Swing trading: NO TRADE today. There is no valid long setup. The chart is in Stage 4 and passes only 2 of 8 Trend Template checks. A breakdown short becomes a watchlist idea only if the stock closes a day below $148.8, and even then the risk review requires a separate review first.
- Day trading: small, conditional, one idea at a time. The VWAP-rejection short and the oversold-bounce long were both approved only at reduced (half) size. The support-breakdown short was rejected because its reward-to-risk was only 1.0. It is currently around 12:23 ET, inside the 11:30–14:00 midday chop window, which the plan says to avoid.
- Options: one defined-risk bearish idea was approved. It is a Dec 18 152/150 bear put debit spread. Maximum loss is $95 and maximum profit is $105. That payoff is thin, about 1.1 times the risk.
- The single most important risk is a violent oversold bounce. RSI2 is 2.6, the price is only 2.2% above its 52-week low, and there is heavy speculative call buying. CEO-succession headlines can also gap the stock in either direction. A short-side idea can be right on the trend and still get stopped out by one sharp rally.
Long-term investment view
Stance: neutral, wait for a better price or better evidence. The fundamental analyst rates the business quality grade A but sets the stance at neutral, with 55% confidence.
What is great about the business: - Operating margin is 60.4%. - FCF (free cash flow) is $96.7B, with 81% conversion. That means most reported profit turns into cash. - Net cash is $51.5B. - Interest coverage is 547x. - Stock-based pay is only 3.0% of revenue, and the diluted share count is falling. - Distress risk is effectively nil (Altman Z of 49.2).
Why the price is still not attractive: - The valuation tools conflict. Cheap multiples (forward P/E 9.2, PEG 0.19) say "bargain." The mechanical DCF gives a probability-weighted value of about $91. The reverse DCF says today's price already assumes about 40% starting FCF growth, against a 25% base case. - A reverse DCF works backward from the current price to find the growth the market is already assuming. - When valuation tools disagree this much says to assume the market may know something you don't. - The DCF may be too harsh. It uses a 13% WACC built on a beta of 1.6. The analyst adjusted the values up to bear $54, base $105 and bull $165. Even the adjusted base case is below $152. - Growth is slowing from a very high level. Revenue growth went 125.9% → 114.2% → 65.5%. Gross margin slipped from 75.0% to 71.1%. - Forensic verdict: WATCH, not red flag. - The Beneish M-Score is -1.27, above the -1.78 threshold, but it is mostly driven by fast growth. - The cash-flow accruals ratio is 59.4%. - Inventory grew 112% against revenue growth of 65%. If demand cools, write-downs could follow. - Data problems lower confidence. The trailing P/E (19.2) and forward P/E (9.2) do not reconcile. The earnings release on 2026-11-17 is out, but its figures and guidance are unknown in our data.
What would prove the wait-stance wrong (falsification): - Turn bullish if: the actual results and guidance show growth well above 40% with gross margin stabilizing at about 70% or higher. - Turn bearish if: hyperscalers cut capex, gross margin falls below about 65%, or revenue growth drops under 20%. - Consider buying if: the price reaches the $100–120 zone, which would offer a real margin of safety.
Swing trading view
No trade. Every swing-relevant lens points down: - Technical (85% confidence): - Price is 25–28% below the key moving averages (SMA50 $210.33, SMA200 $203.46). - ADX is 47 with -DI at 44.6, which signals a strong downtrend. - Pullbacks are getting deeper (12.2% → 14.4% → 47.8%). That is the opposite of a constructive base. - Flow: - 9 distribution days against 2 accumulation days. - Insider activity is sales only: $1,370.53M in 180 days, with no buys. - Macro (HEADWIND): - SPY is only 0.01% above its 200-day average. - VIX is 25.48 and in backwardation, meaning near-term fear is priced above longer-term fear. - The 10-year yield is about 5.06%. - The macro analyst recommends reduced position sizes.
Conditional idea, not a recommendation. A swing short could be considered only after a daily close below $148.8, the 52-week low and the Donchian 20/55-day low. Two cautions apply: 1. The plan's stop is about 8 points away, so only a tiny position fits a $50 risk budget. 2. The plan labels the entry a "buy-stop," but a short would actually use a sell-stop. That kind of error is exactly why the risk review requires a fresh review before acting.
Long swing: wait for all of the following before considering one: - An undercut of $148.8 that closes back above it on strong volume (a "spring"). - A reclaim of the 10- and 21-day EMAs ($168.68 / $184.29). - RSI14 back above 40. - Contracting price ranges that start to form a base.
Day trading view (today / next session)
Context: - NVDA is "in play": relative volume is 3.13x normal. - It trades below VWAP at $153.06. VWAP is the volume-weighted average price, a common intraday reference line. - The day is choppy, with 4 VWAP crosses. - 99% of the average daily range is already used, so little room may be left today. - Regime favors the short side, but RSI2 of 2.6 says bounces can be sharp.
Risk-checked plans (the risk review's verdicts are final):
- VWAP rejection short (approved at reduced size).
- Act only on a clear failed rally into VWAP: a wick or red 5-minute candle while price stays below about $155.46.
- Entry about $152.9, stop $154.0, targets $150.85 then $148.8. Reward-to-risk is 1.86.
- Best windows are 14:00–15:30 ET today, or the next session.
-
Note: the $1.10 stop is only about 0.17x ATR, so normal noise can trigger it.
-
Oversold-bounce reclaim long (approved at reduced size, counter-trend).
- Act only if price undercuts $148.8, reclaims it, and then closes a 5-minute bar above VWAP on volume, while SPY is not weak.
- Entry about $153.3, stop $151.9, targets $155.46 / $158.19.
-
Reward-to-risk is 1.54, barely above the 1.5 minimum, so any slippage erases the edge.
-
LOD/support breakdown short: REJECTED. Reward-to-risk is 1.0, below the 1.5 minimum. Shorting directly into the 52-week low also invites a failed-breakdown reversal. Do not take it.
Account rules: - One idea at a time. Never flip from the short to the counter-trend long in the same stretch of chop. - 1R (one unit of planned risk) is $50. Stop for the day at a $200 loss or 3 losing trades. - Be flat by the close. - Check the PDT rule if this is a US margin account under $25k. The pattern-day-trader rule may limit you to 3 day trades in 5 business days.
Options view
Approved: Dec 18 bear put debit spread, buying the 152 put and selling the 150 put.
| Item | Value |
|---|---|
| Net debit (max loss) | $95 |
| Max profit | $105 |
| Breakeven | $151.05 |
| Days to expiration | 30 |
Why this structure: - IV (implied volatility, the volatility priced into options) is about fair: IV/HV20 is 1.04. Fair IV suits a defined-risk debit spread. - The earnings volatility "crush" has likely already happened, since results came out on Nov 17. - Other structures either break the $100 options-risk cap (long puts cost about $1,908–$2,352 per contract) or fight the trend (put credit spreads).
The honest drawback: breakeven is only about 0.7% below spot, and the profit zone is narrow. A bounce toward $158.99–$168.68 would lose most or all of the debit.
Management: - Enter as a single combo limit order at the mid. - Take profit at 50–75% of the maximum. - Exit on a close above $158.99 or on a failed breakdown at $148.8. - Review around 21 days to expiration (about Nov 27). Close by roughly Dec 8–11. - No adds and no rolls.
Where the analysts disagree
- Cheap or expensive? Forward P/E of 9.2 and PEG of 0.19 say cheap. The DCF (about $91 mechanical, $105 adjusted base) and a 2.64% FCF yield say expensive. Wall Street's mean target is $253.67, which is +67%. My weighting: the DCF and FCF evidence is more trustworthy here. The forward P/E conflicts with the trailing P/E, and low P/Es at peak earnings are a classic semiconductor value trap. Fundamentals win on the investing horizon, and they currently say "wait."
- Trend or bounce? Technical, flow and macro analysts all lean bearish, with confidence of 85, 60 and 68. Yet every analyst warns about an oversold squeeze. For swing and day horizons, the trend gets priority, but sizes stay small and no new shorts are taken into the $148.8 low itself.
- Call buying. Unusual volume in the Dec $205 calls (45,969 traded vs 16,959 open interest) could be bullish speculation. The flow analyst notes that volume alone does not reveal direction or who is on the other side. I treat it as a squeeze risk, not as a signal to buy.
- Leadership news. The flow analyst reports CEO-succession headlines. The forensic analyst notes an 8-K 5.02 officer/director change on Nov 12, with details unknown. I treat this as unverified event risk in both directions, not as a thesis.
What to watch next (catalysts, levels, data)
Earnings details: the actual Q3 FY27 results and guidance (currently unknown). Focus on: - Gross margin versus the 70% line - Revenue growth versus 40% - Inventory and purchase commitments in the 10-Q footnotes
Levels:
| Role | Price | Meaning |
|---|---|---|
| Support | $148.8 | 52-week low |
| Support | $146.8 | Next support |
| Support | $143.27 | Next support |
| Resistance | $158.99 / $162.52 | Pivot levels |
| Resistance | $168.68 | EMA10 |
| Resistance | $184.29 | EMA21 |
- A daily close below $148.8 brings the swing-short review into play.
- An undercut and reclaim of $148.8 is the first bullish clue.
Macro triggers: - SPY closing below its 200-day average. - VIX above 30, or backwardation widening. - The 10-year yield sustained above about 5.2%. - The high-yield spread rising above about 4 points (from 3.43).
Filings: - Who left under the 8-K 5.02. A CFO exit would matter more. - Form 4 details, especially whether insider sales were 10b5-1 plan sales. - Analyst target revisions after earnings.